NEW DELHI: InCred Wealth has clocked over $1.2 billion (Rs 9,000 crore) of Assets Under Management with over 1,600 HNI/UHNI clients in a little over a year, the company said.
“Our domestic clients are spread across over 50 Indian cities with NRI clients present across 10 countries, which highlights the respect enjoyed by our brand and the breadth and innovation of our product offerings,” said Nitin Rao, CEO, InCred Wealth.
The company has roped in senior UHNI bankers like Vivek Kapoor and Nakul Beri. Kapoor has over 18 years of experience in private wealth management and banking across India and the UK, having previously worked at Barclays Wealth and DSP Merrill Lynch.
Nakul has 25 years of Corporate and Private Banking experience across multiple geographies, having worked with CitibankStandard Chartered, Barclays and his last assignment was in Singapore with Union Bancaire Privee.

“I am personally extremely excited about the growth prospects for our Wealth Management business. Our unique blend of innovative products, an entrepreneurial start-up culture and the ability to hire top talent has helped us to hit the ground running with a long runway for growth in the years to come,” said Bhupinder Singh, founder & group CEO, InCred.

Leave a comment

Sanjay Singh

Head of Investment Banking – InCred Capital

Sanjay Singh is the Head of Investment Banking at InCred Capital, where he leads coverage across both advisory and equity capital markets. He brings over 20 years of experience across investment banking, strategy, and operations, with deep expertise in the pharmaceuticals and healthcare sectors. 

Prior to joining InCred, he held leadership roles at BDA Partners as Head of India and Co-Head of Healthcare Asia, and at KPMG as Partner and Head of Life Sciences in India. He has also worked with Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals and is an active participant in industry forums, including CII, FICCI, IDMA, and OPPI. 

His transaction experience includes advising Chemfield Cellulose on its divestment to Oji Holdings, Archimica S.p.A. on its acquisition by PI Industries, Synokem Pharmaceuticals on growth investment from TA Associates, Isagro SpA on the divestment of Isagro Asia Agrochemicals to PI Industries, Sahajanand Medical Technologies on its equity raise from Morgan Stanley Private Equity, Kinedex Healthcare on its majority sale to Eris Lifesciences, Astec LifeSciences on the sale of equity to Godrej Agrovet, Nihon Nohyaku on its acquisition of Hyderabad Chemical Limited, Kilitch Drugs on the USD 52 million sale of its sterile injectables business to Akorn Inc, and Unimark Remedies on raising USD 34 million from Hikma Pharmaceuticals.